Methylpyrrolidone

Methylpyrrolidone

SCHEMBL4564460

C=CCN1CCCC1=O.CN1CCCC1=O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.59
BRD2 P25440 1/20 0.59
PIK3CD O00329 1/20 0.44
TSHR P16473 3/20 0.40
KMT2A Q03164 3/20 0.40
CHRM2 P08172 3/20 0.38
CHRM5 P08912 3/20 0.38
CHRM1 P11229 3/20 0.38
CHRM3 P20309 3/20 0.38
CYP2D6 P10635 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
APEX1 P27695 2/20 0.38
PMP22 Q01453 2/20 0.38
MAPK1 P28482 2/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
CYP1A2 P05177 1/20 0.38
CHRM4 P08173 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30762 0.89
Methane SCHEMBL27440503 0.87 PIK3CD (0.47) PIK3CDTSHRKMT2ACHRM2CHRM5
Ammonia Solution, Strong SCHEMBL28118769 0.87 PIK3CD (0.47) PIK3CDTSHRKMT2ACHRM2CHRM5
Hydrochloric Acid SCHEMBL7162864 0.87 PIK3CD (0.47) PIK3CDTSHRKMT2ACHRM2CHRM5
Ammonia Solution, Strong SCHEMBL11155607 0.85 PIK3CD (0.46) PIK3CDTSHRKMT2ACHRM2CHRM5
SCHEMBL15846768 0.84 PIK3CD (0.46) PIK3CDTSHRKMT2ACHRM2CHRM5
SCHEMBL2574923 0.83 L3MBTL1 (0.44) PIK3CDTSHRKMT2ACHRM2CHRM5
SCHEMBL284047 0.82 L3MBTL1 (0.47) PIK3CDTSHRKMT2ACHRM2CHRM5
Ether SCHEMBL22771109 0.81 PIK3CD (0.43) PIK3CDTSHRKMT2ACHRM2CHRM5
SCHEMBL29212561 0.81 PIK3CD (0.42) PIK3CDTSHRKMT2ACHRM2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961268-B1 SAMPLE FIXATION AND STABILISATION GOLDSBOROUGH ANDREW SIMON (FR) 2018-11-21 EP claimed
EP-2383258-B1 METHOD FOR RAPIDLY METHYLATING HETEROAROMATIC ARENE AND METHOD FOR PRODUCING PET TRACER RIKEN (JP) 2015-09-02 EP claimed
EP-0603418-B1 HERBICIDE COMPOSITION KUMIAI CHEMICAL INDUSTRY CO (JP) 1997-06-18 EP claimed
EP-0531292-B1 PHOTORESIST STRIPPER IBM (US) 1997-01-02 EP claimed
EP-0075784-B1 PROCESS FOR DIRECT GOLD PLATING OF STAINLESS STEEL Kobayashi, Masami (JP) 1986-12-03 EP claimed
US-20210393596-A1 DRUG FOR TREATING TINNITUS SCOTT, LUISA LYNN 2021-12-23 US disclosed
CN-107198686-B Antifungal medicine composition 宝丽制药股份有限公司 2019-07-30 CN disclosed
CN-208632439-U Electronic equipment framework DIC株式会社 2019-03-22 CN disclosed
CN-104662046-A Method for producing modified conjugated diene polymer, polymer composition, crosslinked polymer, and tire JSR CORP 2015-05-27 CN disclosed
CN-104487460-A Method for producing modified conjugated diene polymer, polymer composition, crosslinked polymer, and tire JSR CORP 2015-04-01 CN disclosed
WO-2014102305-A1 METHOD FOR PURIFYING A RECYCLING FLOW FROM A PLANT FOR PRODUCING POLYARYLENE ETHER SULFONES BASF SE (DE) 2014-07-03 WO disclosed
WO-2014102306-A2 METHOD FOR PURIFYING A RECYCLING FLOW FROM A PLANT FOR PRODUCING POLYARYLENE ETHER SULFONES BASF SE (DE) 2014-07-03 WO disclosed
EP-1231877-A4 TRANSDERMAL ADMINISTRATION OF HUPERZINE XEL HERBACEUTICALS (US) 2009-03-18 EP disclosed
CN-101171551-A Composition for removing post etch and ashed photoresist residue and bulk photoresist MALLINCKRODT BAKER INC (US) 2008-04-30 CN disclosed
US-6896898-B1 Transdermal delivery system for alkaloids of aconitum species XEL HERBACEUTICALS, INC. (US) 2005-05-24 US disclosed
US-20040202705-A1 Transdermal administration of huperzine XEL HERBACEUCTICALS, INC. 2004-10-14 US disclosed
US-6585963-B1 Nail compositions and methods of administering same WATSON PHARMACEUTICALS, INC. 2003-07-01 US disclosed
EP-1231877-A1 TRANSDERMAL ADMINISTRATION OF HUPERZINE XEL Herbaceuticals (US) 2002-08-21 EP disclosed
WO-2001035883-A1 TRANSDERMAL DELIVERY SYSTEM FOR ALKALOIDS OF ACONITUM SPECIES XEL HERBACEUTICALS (US) 2001-05-25 WO disclosed
WO-2001032115-A1 TRANSDERMAL ADMINISTRATION OF HUPERZINE XEL HERBACEUTICALS (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393596-A1 DRUG FOR TREATING TINNITUS CHAT, SLC18A2, TRPV1 BRD4 1210/4885BRD2 2951/4885PIK3CD 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.